Paul, Weiss offers a highly experienced shareholder activism defense practice. We help public companies and their boards prepare for, respond to and navigate activist share accumulations, settlements, proxy contests and other hostile campaigns by activist investors. We are deeply familiar with the activist investor playbook, whether the focus is changes to management or directors, a shift in strategy, return of capital, operational changes or pursuing a takeover, break-up or sale of a company. Importantly, we take a commercial, problem-solving and situation specific approach to assessing, advising on and implementing the best way forward.
Merck Overcomes Avoro Challenge to Acceleron Acquisition
- Client News
- November 22, 2021
Paul, Weiss helped Merck navigate an activist hedge fund challenge and successfully consummate its $11.5 billion acquisition of Acceleron, a biopharmaceutical company focused on rare disease treatments, the largest biotech deal completed in 2021.
The Paul, Weiss team included corporate partners Scott Barshay and Laura Turano.